AVX 13616

• Target:

  Others|||Antibacterial

• Related Pathways:

  Microbiology/Virology|||Others

• Bioactivity:

  AVX 13616, Avexa's leading antibacterial candidate, demonstrates significant in vivo antibacterial efficacy, especially against drug-resistant Staphylococcus pathogens, with an IC50 value of 2-4 µg/ml (MICs) and is targeted as an antibacterial agent. Comparable in activity to mupirocin within a nasal decolonization model, AVX13616 necessitated only a single application for effectiveness. This compound, alongside others, exhibited broad-spectrum antibacterial action, achieving MICs of 2-4 micrograms per milliliter against various isolates, including S. aureus, coagulase-negative staphylococci, enterococci, MRSA, VISA, and VRSA. Aimed for topical use and the treatment of wound infection or catheter-related infections, a solitary 5% (w/w) AVX13616 application (roughly equivalent to 2% mupirocin) proved as efficacious as twice-daily 2% mupirocin over five days in decolonizing MRSA in mice.

• Smiles:

  O=C (C (CC (C) C) NC (C (CCCNC (N) =N) NC (C (CCCCN) NC (COC1=C (C2=C (C=CC3=C2C=CC=C3) OCCC (C) C) C4=C (C=CC=C4) C=C1) =O) =O) =O) OCCC (C) C.Cl.Cl

• Molecular Formula:

  C50H73Cl2N7O7

• Molecular Weight:

  955.08

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  900814-48-4